The discovery of a number of these molecular alterations underlying lung cancer has led to uniquely targeted therapies with specific inhibitor drugs such as erlotinib and gefitinib for mutations in the epidermal growth factor receptor (EGFR) [4], [5] or crizotinib for the gene translocation resulting in the EML4-ALK oncogene [6]. The gene discussed is EGFR; the disease is lung carcinoma.